Valuation: Zai Lab Limited

Market Cap 2.91B 22.82B 2.51B 2.36B 2.15B 4.04B 278B 4.1B 27.65B 10.81B 139B 10.92B 10.68B 463B P/E 2026 *
-11.4x
P/E 2027 * -12x
Enterprise Value 2.45B 19.23B 2.12B 1.99B 1.81B 3.4B 234B 3.46B 23.3B 9.11B 117B 9.2B 9B 390B EV / Sales 2026 *
5.8x
EV / Sales 2027 * 4.44x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day-1.19%
1 week+15.47%
Current month+38.88%
1 month+22.37%
3 months+23.43%
6 months+31.00%
Current year+45.49%
1 week 18.34
Extreme 18.34
21.06
1 month 13.88
Extreme 13.88
21.06
Current year 12.31
Extreme 12.31
21.06
1 year 12.31
Extreme 12.31
28.84
3 years 10.56
Extreme 10.56
35.5
5 years 10.56
Extreme 10.56
118
10 years 10.56
Extreme 10.56
151.2
Manager TitleAgeSince
Chief Executive Officer 61 2014-03-31
Director of Finance/CFO 58 2023-07-06
President 62 2022-11-30
Director TitleAgeSince
Chairman 61 2014-03-31
Director/Board Member 83 2016-12-31
Director/Board Member 75 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.19%+15.47% - - 2.91B
+0.76%+0.04%+40.86%+1.47% 80.23B
-1.02%-0.51%-2.54%+28.91% 50.64B
+1.65%-4.13%+10.41%+165.05% 46.87B
-1.39%+1.82%-50.22%-50.44% 46.34B
-0.09%+1.09%+54.07%-19.93% 31B
+2.42%+7.65%+129.21%-39.40% 25.28B
+1.41%+0.28%+43.54%+89.83% 24.36B
+1.65%+0.53%-2.21%+190.26% 20.81B
+3.50%+1.20%+62.21%+119.56% 16.08B
Average +0.76%+0.35%+31.70%+53.92% 37.96B
Weighted average by Cap. +0.58%+0.53%+24.20%+39.33%

Financials

2026 *2027 *
Net sales 423M 3.32B 365M 343M 312M 587M 40.41B 596M 4.02B 1.57B 20.24B 1.59B 1.55B 67.25B 569M 4.46B 491M 462M 420M 789M 54.4B 802M 5.41B 2.12B 27.24B 2.14B 2.09B 90.52B
Net income -245M -1.92B -212M -199M -181M -340M -23.43B -346M -2.33B -911M -11.73B -920M -900M -38.99B -187M -1.47B -161M -152M -138M -259M -17.87B -264M -1.78B -695M -8.95B -702M -687M -29.74B
Net Debt -458M -3.59B -395M -371M -338M -635M -43.76B -646M -4.35B -1.7B -21.91B -1.72B -1.68B -72.83B -381M -2.99B -329M -309M -281M -528M -36.41B -537M -3.62B -1.42B -18.24B -1.43B -1.4B -60.6B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change Volume
26-08-17 HK$19.86 -1.19% 9,728,600
26-08-14 HK$20.10 -2.43% 12,713,400
26-08-13 HK$20.60 +4.73% 19,463,198
26-08-12 HK$19.67 +6.15% 29,358,600
26-08-11 HK$18.53 +5.28% 19,296,100
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
25.90USD
Average target price
32.18USD
Spread / Average Target
+24.25%

Quarterly revenue - Rate of surprise